Form 4: Whitehawk Therapeutics CEO Acquires Shares

David James Lennon, CEO of Whitehawk Therapeutics, Inc., has acquired 51,021 shares of common stock.

Summary

• David James Lennon, Chief Executive Officer and Director of Whitehawk Therapeutics, Inc., reported a transaction on May 14, 2026.
• He acquired 51,021 shares of common stock at a price of $3.92 per share.
• Following this transaction, Mr. Lennon beneficially owns 569,643 shares of common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the CEO's direct investment in the company's stock, signaling confidence.

Positives

• CEO's acquisition of company stock can signal confidence in the company's future prospects.
• The purchase of 51,021 shares indicates a significant personal investment by the CEO.

Future Outlook

No forward-looking statements or guidance are present in this filing.

Industry Context

StockSavvy.ai notes that insider stock purchases, particularly by CEOs, are often viewed positively by the market as they align management's interests with those of shareholders. This transaction at $3.92 per share provides a specific valuation point for this insider's confidence.

Stakeholder Impact

• Shareholders may view the CEO's purchase as a positive signal of confidence in the company's future.
• Employees may be encouraged by the CEO's personal investment, potentially boosting morale.

Key Dates

Recommendation

The acquisition of shares by the CEO is a positive signal, but it is a single transaction and does not provide sufficient information on the company's overall financial health or strategic direction to warrant a stronger recommendation. It suggests confidence but requires further analysis of the company's performance.

Keywords

Form 4, SEC Filing, Insider Trading, Stock Acquisition, Whitehawk Therapeutics, CEO, Beneficial Ownership